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Polycystic Kidney Disease (PKD) is a genetic disorder characterized by a growth 
of multiple cysts in the kidney which, in most cases, culminates in end stage renal failure.  
A clinical case study was done to highlight the clinical manifestations and the 
progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Currently 
there are no treatments or cures for PKD with the exception of dialysis and kidney 
transplantation for patients in kidney failure. Exploration of the role of PKD1 and PKD2 
in cystogenesis had yielded potential treatment alternatives for ADPKD such as the use 
of mammalian target of rapamycin (mTOR) inhibitors to reduce cyst growth and preserve 















 Special thanks to Jacob Stever MSIII for helping me throughout the compilation 
of the case study and for answering my questions as they arise and providing me valuable 
feedback. Also, many thanks to Dr. Josh Baker for his guidance throughout the research 
component of the thesis and to Gina Sella for pairing me with my medical student 
mentor. I would like to also thank Mark Taylor and Jessica Chen for allowing me to refer 







Table of Contents: 
• Abstract……………………………………………………………………….…..i 
• Acknowledgements……………………………………………………………...ii 
• Table of Contents………………………………………………………………..iii 
• List of Tables………………………………………………………………….....v 





o Clinical Feature and Diagnosis……...………………………………....…8 
o Treatment…………………………………………………………….…...9 
o Body of Review and Conclusions………………………………………..11 
• Literature Review………………………………………………………………...13 
o Introduction: mTOR Pathway…..………………………………………..13 
o Methods and Results: Use of mTOR inhibitors…..…………………..….21 
o Discussion and Conclusion………………………………………..…….26 
• Clinical Case Study…………………………………………………………..….28 
o ID and Chief Complaint………………………………………………....28 
o History of Present Illness………………………………………………..28 





o Review of Systems…………………………………….…..…...………..30 
o Physical Exams…………………………………………………………..30 
o Diagnostic Work……….………………….……………………………..32 
o Assessment…………………………………..…………………………...36 
o Treatment Plan ……………..………………………………………....…39 
o Prognosis…………………………………………………………………40 

















List of Tables 
Table 1: Receptor Affinity and actions of various Vascular Endothelial Growth Factors ……..7 




















List of Figures 
Figure 1: PC1/PC2 role in cell signaling of renal cell and its effects...……………………...10 
Figure 2: The effect of RAAS on the development of hypertension in ADPKD patients…….13 
Figure 3: Overview of mTOR Pathway …………………………………….………….15 
Figure 4: Han:SPRD Rat Model Studies ………………………………………….…...24 
Figure 5: Han:SPRD Rat Studies Quantitative ……………………..………………….25 
Figure 6: Orally fed Rapamycin on Han:SPRD Rat Models ……………………….….27 















Introduction: Overview of Disease 
Polycystic Kidney Disease is a common genetic disorder characterized by the 
growth of multiple cysts in the kidney that can potentially culminate in end stage renal 
failure. If intervention is not taken, PKD eventually will result in death. 
There are two main types of Polycystic Kidney Disease. The more common 
Autosomal Dominant Polycystic Kidney Disease (ADPKD) occurs with an incidence of 
1:1000 individuals, and is generally characterized by cyst growth in kidneys, liver, 
pancreas and other organs. The disease is slow progressing and usually results in end 
stage renal disease around the age of 50 3. The second and less common, Autosomal 
Recessive Polycystic Kidney Disease (ARPKD) occurs with an incidence of 1:20000 
individuals, and is an infantile disease characterized by renal cyst formation and 
congenital hepatic fibrosis 3.  
The process of renal cyst growth in ADPKD patients is called cystogenesis. 
Although the exact mechanism of cyst growth is not known, it is commonly believed that 
mutations in the PKD1 or PKD2 genes are the underlying cause. Cystogenesis in 
ADPKD patients is similar to tumor growth: they both exhibit traits such as increased cell 
proliferation, changes in apoptosis and angiogenesis 2. 
Currently the only options available for ADPKD patients are constant monitoring 
of cyst growth, renal function and blood pressure. In cases of end stage renal disease, 





PKD2 mutations in cystogenesis is very important in that it can potentially yield a 
possible alternative treatment option for PKD patients. Currently, studies are being done 
on alternative treatments that focus on altering or inhibiting angiogenesis of cyst growth 
in order to slow or even halt the progression of the disease. These alternative therapies 
include using vasopressin V2 receptor antagonists, mTOR inhibitors and the drug 
ocreotide to treat ADPKD. These treatments, although promising, still need more 
research to be conducted before they can be used 4.  
Pathogenesis 
Mutations in PKD1, PKD2 and PKHD1 are the underlying cause of cyst growth 
on PKD patients. The mutant proteins resulting from these mutations are implicated in 
altering normal cell processes in order to accelerate cyst growth. Polycystin-1 (PC1) and 
Polycystin-2 (PC2), proteins encoded by the PKD1 and PKD2 gene, negatively regulate 
the signaling molecules that elevate cellular growth rate. PKHD1 is the gene that encodes 
fibrocystin, and its mutation is implicated in ARPKD. Figure 1 highlights the role of PC1 






Figure 1: PC1/PC2 role in cell signaling of renal cell and its effects5 
Source: The Cell Biology of Polycystic Kidney Disease 
 
PC1 and PC2 are integral in regulating cell growth in kidneys. In PKD patients, these 
proteins are defective therefore cell growth is unregulated.   
One of the key characteristics of PKD is the gross enlargement of kidneys due to 
the growth of multiple cysts. Cyst growth is similar to tumor growth in that both are 
highly active processes that require oxygen and nutrients to provide energy1. New blood 
vessels and other supplementary structures need to be formed to support the requirements 
for cyst growth. These new blood vessels are formed by a process called angiogenesis. 
Angiogenesis is defined “by sprout formation or by splitting of a pre-existing blood 
vessel”2. There are a number of growth factors that regulate angiogenesis. These include 
vascular endothelial growth factors (VEGF), angiopoietin-1 (ANG-1), angiopoietin-2 
(ANG-2) and other various chemokines2. These growth factors work together to ensure 







Table 1: Receptor Affinity and actions of various Vascular Endothelial Growth Factors2 
Source: Angiogenesis and the Pathogenesis of Autosomal Dominant Polycystic Kidney Disease  
 
The process of angiogenesis is initiated by the binding of HIF-1 (hypoxia 
inducible factor) to an angiogenesis growth factor such as VEGF-A6. This usually occurs 
in regions of the body that are in a hypoxic (oxygen deprived) state. In PKD patients, the 
growing cysts restrict the oxygen flow to the kidneys thereby inducing a hypoxic state 
which promotes angiogenesis. VEGF is up regulated in hypoxic states due to the 
increased HIF-1α levels.  
According to Huang et al, the VEGF-A levels in ADPKD patients were found to 
be six times greater than age matched individual with normal renal function. Upon further 
examination, VEGF-A was detected in cyst epithelial cells. This finding shows that the 
growth factors are found primarily in the regions where cyst growth is evident. The study 






ANG-1 and ANG-2 are regulators in the angiogenesis process. ANG-1 is an 
agonist which down regulates angiogenesis whereas ANG-2 inhibits ANG-1 when 
VEGFs are not present. Hypertension results in an improper balance of ANG-1 and 
ANG-2 resulting in organ damage2. This is extremely prevalent in PKD patients. Many 
novel treatment techniques for PKD is aimed at restoring the angiogenesis growth factor 
imbalance thereby inhibiting and/or retarding cyst growth in the kidney in hopes of 
preserving renal function.  
One of the hallmark manifestations of PKD is hypertension. Numerous studies 
have shown that hypertension is more prevalent in PKD patients than in patients with any 
other renal disease7. Hypertension in PKD patients stem from the increased activation of 
the renin angiotensin-aldosterone system (RAAS).  
 
 
Figure 2: The effect of RAAS on the development of hypertension in ADPKD patients 







As seen in Figure 2, increased activity of RAAS not only affects blood pressure, it 
also promotes mitogenesis (increases mitosis) of the cysts. As cysts grow, renal arterioles 
start to compress leading to ischemia (restriction of blood supply to tissues7) which leads 
to hypertension and the up regulation of angiogenesis.    
As PKD progresses, renal function is diminished. According to Dr. David Woo, 
this is a result of apoptosis of the nephrons in PKD patients. This was determined by 
noticing the presence apoptic DNA fragmentation in polycystic kidneys. This DNA 
fragmentation was not seen in normal kidneys. It is believed that DNA fragmentation 
could have resulted from a mutation8. Although the exact mutation that resulted in the 
apoptic DNA fragments is not known, this discovery provides a reasonable explanation to 
loss of renal function as PKD progresses.  
Epidemiology  
PKD affects both children and adults, with ADPKD affecting 1 in 1000 
individuals and ARPKD affecting 1 in 10000 neonates and children. ADPKD accounts 
for about 3-4% of end stage renal disease cases; which ranks fourth among all kidney 
disease9. There is no known pattern of PKD in certain races or ethnicities.  
Genetics 
ADPKD is a dominant genetic disorder resulting from mutations in PKD1 or 
PKD2 genes. PKD1 and PKD2 encode for polycystin-1 and polycystin-2 respectively. 





arm of chromosome 4. The majority of ADPKD cases result from PKD1 mutation. These 
patients often exhibit more cyst growth and more rapid deterioration of renal function 4.   
ARPKD is a recessive disorder resulting from mutation in the Polycystic Kidney 
and Hepatic Disease 1 gene (PKHD1). PKHD1 encodes for fibrocystin, which is “found 
to localize in the primary cilium and basal body of the renal and bile duct epithelium”4. 
ARPKD is typically seen in younger patients and often results in congenital hepatic 
fibrosis. Unlike that of ADPKD, the majority of the ARPKD patients die from respiratory 
failure or sepsis4.  
Symptoms 
There are numerous symptoms associated with ADPKD, the most common being 
pain in the abdomen and/or lower back, hematuria (blood in urine), high blood pressure, 
increased size of abdomen and kidney failure 10. The pain in abdomen region and the 
increased abdomen size is associated with the increased size of the kidney due to the 
growth of multiple cysts. The increased kidney size starts to push other internal organs, 
resulting in pain. The blood in urine is due to the occasional bursting of cysts in the 
kidney. Other symptoms seen in ADPKD patients include kidney/urinary tract infections 
and kidney stones 10. 
 Symptoms associated with ARPKD include noticeably larger kidneys seen in 
neonates, hypertension, hematuria and proteinuria (abnormal amount of protein in urine). 






Clinical Features and Diagnosis 
 Patients are not usually diagnosed with ADPKD until the fourth or fifth decade of 
life. Before then, these individuals are usually asymptomatic. There are about 1-2% of 
cases where the patient has developed an early onset form of the disease. These 
individuals are characterized as exhibiting symptoms prior to the age of 15 4. During this 
asymptomatic time, the kidney function tends to be stable and does not start to deteriorate 
until the kidney reaches a critical size. Once critical size is reached, kidney function 
rapidly declines 4. When the kidney reaches critical size, patients tend to start feeling pain 
in the lower back/abdomen region, and exhibit occasional blood in urine.  
 ARPKD is diagnosed at much younger ages than ADPKD. Often diagnosed 
during the neonatal period, these patients tend to display symptoms of respiratory distress 
or noticeably large kidneys4. Many of these patients develop congenital hepatic fibrosis, 
which is characterized by increased fibrosis of portal tracts and the abnormal 
development of biliary ducts. These patients often die of respiratory complications rather 
than renal complications4. Abnormal lab finding indicative of ARPKD include elevated 
creatinine levels, hematuria, proteinuria and enlarged kidneys4. According to Halvorson 
et al, the later the onset of ARPKD symptoms in a particular patient, the better the 
outcome of the patient. Studies show survival rates for ARPKD patients that start to 
exhibit symptoms at age 9 rather than as an infant have been as high as 80%4.  
 Hypertension is a clinical feature especially important in PKD patients. 
Hypertension, defined as having a resting systolic/diastolic blood pressure of above 





pressure commonly precedes loss of renal function. Furthermore, it has been found that 
hypertension is more prevalent in patients with PKD than patients with other renal 
diseases. Therefore, hypertension is a good indicator to determine if a patient has PKD 
and also an indicator for level of kidney function7. 
 In order to confirm that a patient has PKD, an ultrasound, computerized 
tomography (CT) scan, or a magnetic resonance imaging (MRI) scan is performed. These 
scans allow the physician to see the enlarged kidney and the presence of multiple cysts 10. 
These scans also allows for the nephrologist to monitor the progression of the disease4. 
The patient’s family history can also be referenced.  
Treatment 
There are currently no cures for PKD. The current treatments for PKD rely on 
treating symptoms and the clinical features of the disease. For cases of end stage renal 
failure, dialysis and/or kidney transplantation are needed.  
Often fatalities due to PKD result not from the polycystic kidneys themselves but 
from numerous other complications resulting from the eventual buildup of toxic wastes in 
body. Therefore treatments for PKD are focused on preserving kidney function. The most 
common recommendations made by nephrologists include stopping smoking, restricting 
the consumption of caffeine and maintaining a healthy blood pressure4. Essentially, the 
healthier the individual, the better chance he or she will have with maintaining stable 





Treating hypertension is very important in preserving the function of the kidney. 
Severe hypertension can lead to ischemia in the kidney resulting in up regulation of 
angiogenesis. This leads to increased cyst growth which leads to hypertension and so on 
(Refer Figure 2). ACE inhibitors, such as Enalapril, inhibit RAAS and have been shown 
to be especially effective7. Other blood pressure medications, such as Norvasc, a calcium 
channel blocker, and atenolol, a β-blocker, are also effective in slowing the progression 
of the disease4. 
 There are a number of options to treat pain associated with the enlarged kidneys. 
Non-steroidal anti-inflammatory drugs (NSAIDs) should not be taken due its side effects 
on the kidney. Therefore narcotics usually are used, but only during minor episodes of 
severe pain. This is done to minimize addiction to the narcotics4. There are also surgical 
options that can potentially reduce pain. Cyst decortication is a surgical procedure that 
removes cysts. This surgery is usually performed laparoscopically. Though effective in 
the short term, this procedure has numerous side effects including worsened 
hypertension, post-operative bleeding, arrhythmia and even death4.  This procedure is 
usually used in cases of severe pain. Another surgical option that is very effective in 
treating pain is renal artery embolization. This surgical procedure essentially blocks the 
renal artery by purposely forming an embolism. The procedure effectively renders the 
kidney useless, eliminating any remaining renal function (glomerular filtration rate is 
zero). Therefore, this procedure is primarily done on patients who are on dialysis and 





very effective in treating pain and hematuria. It also has minimal side effects which 
include nausea, vomiting and temporary flank pain4. 
In cases of urinary tract infections, antibiotics are prescribed. Cyst penetrating 
antibiotics such as trimethoprim-sulfamethoxazole and fluoroquinolone are commonly 
prescribed specifically to PKD patients4.  
 In cases of renal failure, dialysis and/or kidney transplantation is required. 
Dialysis is a machine that filters blood from all the toxins that a healthy kidney would 
usually filter. In essence the dialysis machine takes over the role of the kidneys. Dialysis 
treatment is often very restrictive on one’s lifestyle. There are numerous dietary and fluid 
restrictions. Transplantation is often the best option for PKD patients in kidney failure. 
Post-transplantation, renal function improves significantly4. Furthermore kidney 
transplantation allows for the patient to essentially live a normal life with little to no 
restrictions, unlike those on dialysis. Kidney transplant recipients are usually placed on 
immunosuppressive drugs indefinitely to deter organ rejection. 
Body of Review and Conclusions 
 Polycystic Kidney Disease is a prevalent disorder that afflicts millions of people 
worldwide. Currently there are no cures to the disease only treatments that help alleviate 
symptoms or to slow progression of renal failure. According to the US Department of 
Health and Human Services, as of November 2013 there are about 100,000 individuals 
waiting for a kidney transplant, and more and more people are being added every day as a 





the many that have yet to find out they have the disease. Understanding cell signaling and 
processes involved in cyst development has shed light on possible treatments that can 
potentially cure the debilitating disease.   
 The use of mTOR inhibitors have been a promising alternative to the current 
therapies for PKD patients. Chapter 2 highlights the mTOR pathway in renal epithelial 


















The majority of Polycystic Kidney Disease cases result from a mutation in the 
PKD1 gene which encodes for the protein polycystin-1. The resulting defective 
polycystin-1 protein inappropriately interacts with another protein, tuberin, thereby up 
regulating the mTOR pathway in cyst lining epithelial cells of PKD patients11. The 
mammalian target of rapamycin (mTOR) is a protein that regulates cell growth and 
protein synthesis via direct and indirect phosphorylation12.  Currently, studies have 
shown that the use of mTOR inhibitors such as sirolimus (rapamycin) are effective in 
slowing cyst growth, preserving renal function and inhibiting cell proliferation in PKD 
patients. The use of mTOR inhibitors offers us a better treatment option for PKD patients 
and also offers us a better understanding of the mechanism behind the abnormal cyst 
growth. 
INTRODUCTION 
The mTOR Pathway  
 Mammalian target of rapamycin (mTOR) is a signaling protein belonging to the 
serine/threonine kinase family that regulates cell growth, metabolism and survival. Its 
improper activation has been observed in numerous medical disorders including cancer 
and the aforementioned polycystic kidney disease13. mTOR signaling utilizes numerous 
intracellular and extracellular signals to promote cell proliferation. 
 mTOR is found in two major protein complexes: mTORC1 and mTORC2. These 





anabolic processes such as protein and lipid synthesis. The overall function of mTORC2 
is not well known but it has been noted that it promotes cell metabolism and cytoskeleton 
organization13. Due to their different interactions with rapamycin, mTORC1 is considered 
rapamycin sensitive and mTORC2 is considered rapamycin insensitive. Despite 
mTORC2 being rapamycin insensitive, it can still be inhibited by large amounts of 
rapamycin13.  
Composition of mTOR complexes 
 mTORC1 is composed of five parts: mTOR, Raptor, mammalian lethal with 
Sec13 protein 8 (mLST8, also known as GbL), proline- rich AKT substrate 40 kDa 
(PRAS40), and Deptor. mTOR is the principle component, Raptor is the regulatory 
associated protein, mLST8 is another associated protein whose role is not known and 
PRAS40 and Deptor are down regulatory proteins of mTORC113.   
 mTORC2 is comprised of six different proteins: mTOR, rapamycin-insensitive 
companion of mTOR (Rictor), mammalian stress-activated protein kinase interacting 
protein (mSIN1), protein observed with Rictor (Protor-1), mLST8 and Deptor. As with 
mTORC1, mTOR is the principle component and Deptor is the inhibitory protein. Rictor 
and mSIN1 interact together for protein stabilization. The role of Protor-1 is not entirely 
known, except for that it interacts with Rictor. Unlike with mTORC1, mLST8, though 
not entirely understood, is essential for the entire complex to function. In mTORC1, 







mTOR Signaling   
 
Figure 3a: Overview of mTOR Pathway – Highlights the activation of mTORC1 and 








Figure 3b: Overview of mTOR pathway – Highlights how mTOR activation is initiated 
via IGF-1/insulin receptors and the various phosphorylations of downstream targets15 
Source: http://www.asnneuro.org/an/005/e108/an005e108f01.htm?resolution=HIGH 
 
 Amino acid availability, presence of growth factors, states of hypoxia and energy 
stress regulate mTORC1 activity3. Through the use of various downstream regulators, 
mTORC1 promotes protein and lipid synthesis. One of the most important regulators for 
mTORC1 is the tuberous sclerosis complex (TSC). TSC is composed of two subunits, 
hamartin (TSC1) and tuberin (TSC2)13. The TSC complexes act as down regulators for 
mTORC1. This is accomplished via the dephosphorylation of the GTP bound Rheb 
protein. Though the exact mechanism of Rheb and mTORC1 interaction is not known, it 
has been shown that the dephosphorylated Rheb protein fails to interact with mTOR1 





tuberous sclerosis occurs. Tuberous sclerosis is characterized by the presence of 
numerous benign tumors and a large number of disorganized cells13.  
 Growth factors such as insulin receptor substrates and insulin like growth factor-1 
(IGF-1) strongly promote mTORC1 activity. These growth factors stimulate the insulin 
receptor pathways which in turn phosphorylates TSC2 via protein kinase B (PKB also 
known as AKT), which inactivates TSC2 (Figure 1a, 1b). This activates mTORC1. In 
addition, growth factors also activate mTORC1 in a TSC1/2 independent manner. This is 
accomplished by the growth factors directly activating AKT, which promotes 
phosphorylation and dissociation of PRAS40. PRAS40 is an inhibitor is mTORC1 
activity therefore its removal results in mTORC1 activation13. As seen in Figure 1b, when 
insulin binds to the insulin receptor, the insulin receptor substrate (IRS) is activated and 
tyrosine kinase activity of the receptor is stimulated. As a result, phosphoinositide 3-
kinase (PI3K) and AKT activity is increased thus resulting in mTORC1 activation. The 
activated mTORC1 represses the PI3K-AKT activity via a negative feedback 
mechanism13.  
 The energy level of the cell also plays a role in mTORC1 activity. When energy is 
low, AMP-activated protein kinase (AMPK), which is “a master sensor of intracellular 
energy status,” phosphorylates TSC2, thereby increasing GAP activity towards the Rheb 
protein, eventually resulting in reduced mTORC1 activity13. This is done to divert energy 
resources to other vital cell functions rather than cell growth and proliferation.  
 Oxygen deprived states restrict mTORC1 activity. The reduction of ATP which 





Hypoxia also down regulates mTORC1 via regulation of DNA damage 1 (REDD1). 
REDD1 restricts mTORC1 by releasing TSC2 from growth factor associated proteins13. It 
is believed that this process evolved to save energy in conditions where growth factors 
are present but oxygen is not13.  
 Presence of amino acids up regulate mTORC1, however it is done independent of 
TSC1/2 activity. Leucine, which is critical for mTORC1 stimulation, is transported into 
the cell via the export of glutamine. In the presence of amino acids such as leucine, Rag 
proteins interact with mTORC1. The Rag proteins bind to Raptor of mTORC1 which 
causes the entire complex to relocate near its activator Rheb protein13.  
Protein synthesis is up regulated by phosphorylating the eukaryotic initiation 
factor 4E (eIF4E)- binding protein 1 (4E-BP1) and the p70 ribosomal S6 kinase 1 
(S6K1)13. This then inhibits the binding of 4E-BP1 to eIF4E which allows for ribosomal 
translation. Furthermore, the activated S6K1 stimulates mRNA formation, elongation, 
and the translation of ribosomal proteins (Figure 1a)13.  
mTORC1 also limits autophagy. According to Laplante et al, autophagy is 
“catabolic process that is important in organelle degradation and protein turnover.” 
Autophagy is a natural process that often occurs when resources are limited in order for 
the cell to continue anabolic processes such as protein synthesis. Autophagy inhibition is 
the result of the interaction of the activated mTORC1 with unc-51-like kinase 1 (ULK1), 
autophagy-related gene 13 (ATG13) and focal adhesion kinase family-interacting protein 





that ULK1 and ATG13 is phosphorylated by mTORC1 thereby inactivating them and the 
autophagy process13. 
mTORC1 positively regulates lipid synthesis. mTORC1 up regulates transcription 
factors involved in genes that encode proteins for lipid and cholesterol synthesis. Sterol 
regulatory element binding protein 1 (SREBP1) and of peroxisome proliferator-activated 
receptor-g (PPARg) are two transcription factors specifically regulated by mTORC113. 
Furthermore, lipin-1, a protein involved in lipid synthesis is phosphorylated by mTORC1 
thus stimulating lipid biosynthesis (Figure 1b)13. 
mTORC2 activity is essential for cell survival, metabolism and proliferation. It 
activates AKT via the phosphorylation at two sites: first by PDK1 at the Thr308 site, and 
second by mTORC2 at the Ser473 site13.  Once phosphorylated, the activated AKT 
inhibits the TSC1/2 complex which promotes mTORC1 activity. mTORC2 activity is 
also important in cytoskeletal organization. Though the exact mechanism is not known, it 
has been shown that mTORC2 phosphorylates protein kinase Cα (PKCα) and paxillin, a 
signal transduction adapter protein, both of which are important in cytoskeletal 
organization13. mTORC2 activity is exemplified in Figure 1b.  
mTOR activity in Polycystic Kidney Disease 
 It is well known that in PKD, mTOR activity is significantly up regulated. A 
number of studies show that the defective polycystin-1 (PC1) inappropriately interacts 





 In healthy renal cells, the cytoplasmic tail of PC1 forms a complex with tuberin 
which functions to repress mTOR activity11,16. Studies show that PC1 protects TSC2 
from inactivation from AKT and that it interacts with TSC2 independent of AMPK 
activation of TSC216. In PKD patients, the PC1 is defective; therefore, it cannot form the 
complex with TSC2 and repress mTOR activity.  
 Further studies indicate the increase levels of IGF-1 in cysts of polycystic 
kidneys17. As seen in Figure 1b, IGF-1 activates the IGF1/insulin receptor which initiates 
the downstream phosphorylation of various targets ultimately stimulating mTOR activity.  
 Table 1 highlights the effects of aberrant mTOR signaling in polycystic kidneys 
and the model organisms used to determine the end results. All of these problems 
contribute to epithelial cyst growth and proliferation in polycystic kidneys.  
 
Table 2: mTOR Signalling in Polycystic Kidneys – Numerous studies were done on 
various model organisms to determine the negative effects of abnormal mTOR activation 
in PKD patients. The negative consequences are shown in the table above.  
Source: Edelstein, Charles L., Mammalian target of rapamycin and caspase inhibitors in 







METHODS AND RESULTS 
Effects of Rapamycin on PKD 
 Rapamycin is a known inhibitor of the mTOR pathway. It is derived from the soil 
bacteria Streptomyces hygroscopicus. Rapamycin directly inhibits mTORC1 activity and 
possibly can even inhibit mTORC2 activity at higher doses (refer Figure 1a, 1b)13. 
Therefore, it has been proposed that the use of rapamycin can be used to slow down the 
progression of PKD by inhibiting the mTOR pathway. This hypothesis has been shown 
somewhat valid by various experiments on rat models.  
Han:SPRD rat model study 
 Three studies were done on Han:SPRD rats in order to determine the effects of 
inhibiting the mTOR pathway in rats with PKD. In the study there were four 
experimental groups: the first group consisted of wildtype male rats (+/+), the second 
group consisted with wildtype male rats treated with rapamycin (+/+ rapa), the third 
group consisted of male rats with PKD that did not receive rapamycin treatments (Cy/+) 
and the fourth group consisted of male rats with PKD that received rapamycin treatment 
(Cy/+ rapa). The first two groups served as controls. The rats had free access to tap water 
and food12,17,18. 
The first experiment determined rapamycin effects on rats when injected 
intraperitoneally (injected directly into body cavity)18. The rapamycin treated groups 
were administered with 0.2 mg drug/kg body weight per day of rapamycin 





ethanol vehicle. After 8 weeks the kidneys from the mice were examined17. Both kidneys 
were removed and weighed. The left one then was “fixed in 4% paraformaldehyde in 
PBS for 120 min and then put into 70% ethanol and embedded in paraffin for histologic 
examinations”18. The resulting kidneys are shown in Figure 2.  
 
Figure 4: Han:SPRD Rat Model Studies – The kidneys from the mice in each of the 
three experimental groups. A is a kidney from the normal control group. B is a kidney 
from the PKD mice that were not treated with rapamycin. It shows significant cyst 
growth in the renal tubular cells as seen by the increased size of the kidneys and the 
presence of increased growth (cysts) surrounding the kidney. C is a kidney from the PKD 
mice that were treated with rapamycin. It is clearly evident that rapamycin slowed the 
growth of cysts in the kidneys as seen by the decrease of cysts surrounding the kidney. 
Source: Edelstein, Charles L., Mammalian target of rapamycin and caspase inhibitors in 
polycystic kidney disease 
 
Rapamycin treatment in these rats showed significant effects on polycystic kidneys. 
Rapamycin treated rats clearly showed repressed renal growth. Specifically it showed a 
65% decrease in total kidney/total body weight ratio, 40% decrease in cyst volume 
density as compared to the polycystic kidneys without rapamycin treatment.  The 
decrease in total kidney/total body weight ratio and cyst volume is evident of suppressed 
cystogenesis. It is clear that rapamycin treatment decreased the number of cysts in the 





decrease in cyst volume density and total kidney/body weight ratio. In addition, the blood 
urea nitrogen (BUN) of the kidneys was tested using a Beckman autoanalyzer18. The 
rapamycin treated polycystic kidneys showed 59% decrease in BUN17. This decrease in 
BUN is indicative of improved renal function. These results are showed in Figure 3 
below.  
 
Figure 5: Han:SPRD Rat Studies Quantitative Analysis – The above figures (D-E 
respectively) show the total kidney/body weight ratio (2K/TBW), cyst volume density 
and BUN levels for all groups tested. +/+ is control group and the Cy/+ is the PKD 
afflicted group. Rapamycin treated groups are indicated on the figures (rapa).  
(D) The total kidney/total body weight ratio was unaffected by rapamycin in +/+ rats. 
Cy/+ rats had a more than doubling of kidney size compared with +/+ controls. 
Rapamycin reduced the kidney enlargement in Cy/+ rats by 65%. (E) The cyst volume 
density was significantly increased in vehicle-treated Cy/+ rats. Rapamycin reduced the 
cyst volume density by 40%. (F) BUN was unaffected by rapamycin in +/+ rats. Cy/+ rats 
exhibit kidney failure like symptoms as indicated by almost a doubling in BUN levels. In 
the Cy/+ rats treated with rapamycin, BUN levels were not nearly as increased as in Cy/+ 
rats without rapamycin treatment18.   
Source: Tao et al., Rapamycin Markedly Slows Disease Progression in a Rat Model of 






A second study was done on the same types of rats, except this time rapamycin 
was fed orally. The experimental group was given 2 mg drug/kg body weight orally per 
day via drinking water  for three months12. The results were similar to the first 
experiment in that there was an overall decrease in BUN, kidney size and cyst volume 
density. According to Edelstein, “there was a 39% decrease in BUN, a 34% decrease in 
serum creatinine, a 26% decrease in kidney size, and an 18% decrease in cyst volume 
density in PKD rats that were treated with rapamycin” orally. The results are displayed in 
Figure 4.  
  
Figure 6: Orally fed Rapamycin on Han:SPRD Rat Models – A and B show BUN and 
serum creatinine levels from the four groups respectively, C and D show the cyst volume 
density (CVD) and total kidney/body weight ratio of the four groups respectively. 










A shows a 39% difference in the BUN in Cy/+ without rapamycin treatment when 
compared to the Cy/+ with rapamycin. B shows a 34% difference in in serum creatinine 
levels in Cy/+ without rapamycin treatment when compared to the Cy/+ with rapamycin. 
In both graphs, it is evident that BUN and creatinine levels were much higher in Cy/+ rats 
than the +/+  rats. C shows that CVD in +/+ rats were essentially unaffected with 
rapamycin treatment. Cy/+ rats showed increased CVD with the rapamycin treated rats 
showing a 18% smaller CDV that the untreated rats. D shows that the 2k/TBW ratio in 
+/+ rats were much smaller than the Cy/+ rats. Rapamycin treatment did not affect the 
ratio in +/+ rats. Cy/+ rats with rapamycin exhibited kidneys that were 26% smaller than 
the untreated rats12.  
Source: Wahl et al., Inhibition of mTOR with sirolimus slows disease progression in 
Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD) 
 
 A third study was done on these rats, except this time everolimus was used 
instead of rapamycin. This study was done to determine whether other mTOR inhibitors 
would cause the same effects as rapamycin. Everolimus is a derivative of sirolimus 
(rapamycin) and follows a similar mechanism as sirolimus in inhibiting the mTOR 
pathway. The experimental PKD rats were given 3ng drug/kg body weight per day for 5 
weeks. Edelstein reports that “there was a 48% decrease in cyst volume density, a 30% 
decrease in BUN, and a 24% decrease in body weight in PKD rats that were treated with 
everolimus.” 
 No matter the method of ingestion of mTOR inhibitors or the type of mTOR 
inhibitor used, the PKD rats treated with mTOR inhibitors showed significant benefits 
from these drugs. However, treatment with rapamycin did not completely suppress the 
progression of the disease but rather slow the progression and prolong renal function 






DISCUSSION AND CONCLUSION 
 The studies on Han:SPRD rats showed the potential benefits of the use of mTOR 
inhibitors for PKD treatments. These results, though promising, still are not enough to 
become a viable treatment option for PKD patients. The results from the use of mTOR 
inhibitors in humans with PKD are not as impressive as in mice or rats. Sirolimus and 
similar drugs are immunosuppressants often prescribed to organ transplant recipients11. 
The immunosuppressive effects can cause other numerous problems such as the 
emergence of opportunistic pathogens. Therefore, the amount of mTOR inhibitors needed 
to retard the progression of PKD might too great for patients to tolerate. In addition, the 
overall decline of total kidney volume does not necessarily correlate with improved 
glomerular filtration rate (GFR) in humans19. As a result it is hard to determine whether 
mTOR inhibitors directly improve GFR or if it affects a supplemental mechanism that 
may or may not improve overall renal function. Furthermore, PKD progresses much more 
slowly in humans than in mice or rats (decades compared to weeks). As a result, the 
effects of mTOR inhibitors on PKD kidneys in humans are hard to distinguish19.  
 The mTOR pathway is a highly complex and intricate system important in the 
pathogenesis of PKD. Hypothetically, inhibiting this pathway potentially can impede the 
progression of this disease. Unfortunately more studies need to be conducted in order to 
determine its efficacy in treating the disease.  
Future research includes treatments targeting other underlying causes of PKD; for 
example targeting the fluid secretion in renal cysts. It is believed that fluid secretion into 





cAMP5. A possible therapy that could be researched is the use of mTOR inhibitors in 




















Clinical Case Study 
Chief Complaint:  
Max Powers is a 29-year-old Caucasian male that works in health care and 
presents for an annual evaluation and a new complaint of persistent high blood pressure 
as measured by himself on several occasions.  
History of Present Illness: 
 Mr. Powers is a 29-year-old Caucasian male that presented to the office for his 
annual exam and a new complaint of persistently elevated blood pressure on multiple 
occasions. He works in a local hospital as a nurse and began to measure his blood 
pressure periodically 2 months ago after developing headaches several times per week. 
He notes that his blood pressure ranges from 130-150/80-100 every day and does not 
correlate with stress, time of day, or whether he is on or off shifts at the hospital.  Mr. 
Powers states that he has not been evaluated or seen a physician for several years but 
does remember being told that his blood pressure was somewhat elevated in the past and 
opted to try improving his blood pressure through a low sodium-healthy diet and 
exercise. He states that while he has been able to somewhat improve total weekly 
exercise, he has only made some minor improvements to his diet, which primarily 
included cutting out fast food and take out foods.  
On further questioning, he denies any visual changes/deficits, chest pain, palpitations, 
diaphoresis (sweating), shortness of breath, flank pain/dysuria/hematuria, 





smoke, and drinks only occasionally in moderate amounts. His only medications include 
Claritin 10mg a day only during allergy season. When he feels really miserable he may 
take an additional one to two capsules of 25mg Benadryl (diphenhydramine). He states 
that this treatment for his seasonal allergies is working. 
Medications: Claritin (10mg a day) only during allergy season, occasional Benadryl 
(25mg) only if necessary  
Allergies: No known drug allergies (NKDA) 
Past Medical History: Prior hypertension diagnosis (opted to manage with diet and 
exercise), seasonal allergies  
Social and Family History: 
 As noted above, he denies smoking or any illicit drug use. He drinks alcohol only 
occasionally and usually at parties or social functions. However, he denies ever drinking 
over his limit. Max Powers is an otherwise healthy individual who habitually works out 
every day. He works in the local hospital as a nurse. He lives with his girlfriend of two 
years in an apartment in the suburbs. He primarily has a Pescetarian diet, however he 
occasionally eats other meat products. 
For family history he stated that his father died at the age of 62 due to a heart 
attack and vaguely remembers that his father had kidney cysts. His mother has a history 
of hypertension. He has a younger sister that is healthy. There is no history of any forms 





Review of Systems: 
General: No fever or chills 
HEENT: No irritation or photophobia, ringing in ears (tinnitus), sore throat or dysphagia 
Cardiovascular: no shortness of breath or chest pain 
Respiratory: Denies coughing or trouble breathing 
Gastrointestinal: Denies irregular bowel movements or abnormal appetite 
Genitourinary: denies hematuria, dysuria or incontinence 
Musculoskeletal: denies any joint or muscle pain 
Psych: No mood swings, anxiety or depression. Some stress due to work  
Neuro: occasional mild headaches  
Physical Exam: 
Max’s vital signs, as recorded by the nurse, are as follows: 
Height: 72”  Weight: 169lbs   Blood Pressure (systolic/diastolic):  
152/91 Temperature: 98.4 oF BMI: 23   HR: 74  RR: 14 
Physical exam findings for Max are as follows: 





HEENT: Pupils are round and reactive to light, sclera are clear, No apparent ocular 
discharge, no visual or hearing deficits. No nasal obstruction or discharge, no apparent 
nosebleeds or hoarseness of voice. Fundoscopic exam was normal, no signs of Arterio-
venous nicking.  
Neck: supple, no carotid bruits, trachea midline, no lymphadenopathy 
Respiratory: No shortness of breath, no wheezing or crackles or rhonchi (clear to 
auscultation bilaterally) 
Cardiovascular: Normal heart rate and rhythm, normal S1 and S2, no murmurs, rubs or 
gallops. No peripheral edema 
Gastrointestinal: Normal bowel sounds, no tenderness to palpation, no rebound or 
guarding, no masses or hepatosplenomegaly.  
Back: Mild costovertebral angle tenderness on left greater than right, no midline 
tenderness 
Genitourinary: no rash, erythema, swelling or lesions noted, no scrotal or testicular 
masses, no penile discharge 
Musculoskeletal: no restriction in movement, all limbs have complete range of motion. 
No cyanosis or clubbing 
Skin: No visible rashes, lesions or ulcerations 
Neurological:  Normal proprioception and gait. All reflexes are normal. Cranial nerves 







CBC       Actual   Normal Range 
WBC       7.0   4.0-10.5 K/µl 
RBC       4.7   4.14-5.8 M/µl 
Hemoglobin      13.9   12-16g/dL 
Hematocrit      40.3   37-47% 
Mean Corpuscular Volume (MCV)   86.2   77-97fL 
Mean Corpuscular Hemoglobin (MCH)  27.5   37-33pg 
MCHC      32.3   30-35g/dL 
Red Cell Distribution Width (RDW)   14.0   12.0-16.2% 
Platelet Count      188   150-400k/µL 
Differential: 
Neutrophils      67.3   44-72% 
Abs Neutrophils     6.0   1.8-7.7K/µL 
Lymphocytes      29.7   22-41% 





Monocytes      2.0   1-9% 
Eosinophils      0.4   0-6.0% 
Basophils      0.5   0.5-1.0% 
CHEMISTRY: 
Comprehensive Metabolic Panel: 
Sodium     138   135-145mmol/L 
Potassium     4.6   3.6-5.5mmol/L 
Chloride     108   96-112mmol/L 
CO2      25   20-33mmol/L 
Anion Gap     5.0 
Glucose     98    65-99mg/dL 
Blood Urea Nitrogen (BUN)   32    6-24mg/dL 
Creatinine     1.5    .76-1.27mg/dL 
GFR Non-African American    58             >59ml/min/1.73 
Calcium     9.8    8.4-10.2mg/dL 
Aspartate Amino trans   18    12-45U/L 





Alkanine Phosphatase    79    30-99U/L 
Bilirubin Total    0.8    0.1-1.5mg/dL 
Albumin     4.1    3.2-4.9g/dL 
Total Protein     6.8    6.0-8.2g/dL 
Globulin     2.7    1.9-3.5g/dL 
A/G ratio     1.52 
Phosphorus      3.0    2.5-4.5mg/dL 
Magnesium     1.7    1.5-2.5mg/dL  
LIPIDS 
Cholesterol     151    <200mg/dL 
Triglycerides     135    <150mg/dL 
HDL      49    >40mg/dL 
LDL      75    <100mg/dL 
URINALYSIS: 
Color     slight yellow 
Appearance    clear 





pH     6.0     5.0-8.0 
Glucose    Negative    Negative 
Ketones    Negative    Negative 
Bilirubin    Negative    Negative 
Blood     Trace     Negative 
Protein     Trace     Negative 
Nitrites                                                Negative     Negative 
Leukocyte Esterase   Negative    Negative 
WBC     2-5/hpf    none 
RBC     20-30/hpf    none 
Epithelial Cells   none     none 
Bacteria                                               none     none 
Dysmorphic Red Cells  none                 none 
RENAL ULTRASOUND REPORT: 
Findings: Enlarged kidneys (14-16cm in length, 8-10cm in width), with three bilateral 
renal cysts on the left kidney (sizes varying from 2-5cm). The cysts are non-
communicating and the kidneys do not have smooth contours. There are no cysts on liver 








Figure 7: Renal Ultrasound of patients left kidney – There is a presence of 3 renal 
cysts on his left kidney which points to possible ADPKD.  
Assessment 
Max is a 29 year old male with past medical history of persistent hypertension. For a 
relatively healthy individual at such a young age, this raised numerous red flags. A 
hypertension workup was done in order to figure out the cause of his hypertension. The 
workup included a complete blood count with chemistry panel and lipid panel, urine 
analysis, and a renal ultrasound. His blood test indicated possible renal dysfunction due 
to abnormal BUN, creatinine and GFR. The urine analysis showing trace amounts of 
blood further confirmed this theory. The renal ultrasound showed the presence of 
multiple cysts which are likely contributing to his renal dysfunction. Furthermore the 
ultrasound noted no renal artery stenosis. A lipid panel was done in order to assess 
cardiovascular disease risk in a new patient with Stage 1 hypertension. His lipid values 






• Autosomal Dominant Polycystic Kidney Disease 
• Multiple Benign Cysts 
• Acquired Renal Cystic Disease 
• Tuberous Sclerosis 
• Medullary Cystic Disease 
• Autosomal Recessive Polycystic Kidney Disease 
Multiple Benign Simple Cysts – Multiple benign cysts is relatively common in the adult 
population. This is not likely the case with Max because it is not common in a patient 
under the age of 30 and it is generally found in a more elderly population 20.  
Acquired Renal Cystic Disease – Characterized by the developments of many fluid filled 
cysts in patients with no history of hereditary cystic disease 21. This is probably not the 
case with Max due to the presentation of his kidneys. Kidneys of Acquired Renal cystic 
disease are usually small and of normal size with smooth contours, whereas Max’s 
kidneys are abnormally large and does not have smooth contours 20.  
Tuberous sclerosis – Disease characterized by the growth of numerous benign tumors in 
the brain and other vital organs such as the kidneys, eyes or skin. Many patients with 
tuberous sclerosis often present with multiple cysts in the kidney. Diagnosis of tuberous 
sclerosis “requires two major features (renal angiomyolipoma, facial angiofibromas or 
forehead plaques, nontraumatic ungual or periungual fibroma, three or more 





tuber, subependymal nodule, subependymal giant cell astrocytoma, cardiac 
rhabdomyoma, lymphangioleiomyomatosis) or one major plus two minor features 
(multiple renal cysts, nonrenal hamartoma, hamartomatous rectal polyps, retinal achromic 
patch, cerebral white matter radial migration tracts, bone cysts, gingival fibromas, 
"confetti" skin lesions, multiple enamel pits)” 20. In Max’s case, the presence of multiple 
cysts is the only symptom; therefore he does not have tuberous sclerosis. 
Medullary Cystic Disease – condition where cysts grow in the medulla of the kidney 
eventually leading to end stage renal failure. Kidneys usually are normal sized. Patients 
with medullary cystic kidney disease tend to also have hyperuricemia and gout 20.  Max 
probably does not have this disease because he does not have gout like symptoms.  
Autosomal Recessive Polycystic Kidney Disease (ARPKD) – Polycystic kidney disease 
found primarily in infants or children. It is caused by a mutation in the PKDH1 gene. 
Patients with ARPKD often present with other complications as well including congenital 
hepatic fibrosis 4. Unlike in ADPKD, extrarenal cysts are not as common. Severe 
systemic hypertension is prevalent in young patients, however the hypertension seems to 
subside as the patient ages with some patients even returning to normotensive states 4. 
Due to the age of Mr. Power’s is experiencing his symptoms, and the lack of symptoms 
Max is experiencing, ARPKD does not seem likely.  
Diagnosis 
After careful review, Mr. Powers was diagnosed with Autosomal Dominant 





and creatinine levels which indicated renal dysfunction. Furthermore, the urine analysis 
which showed trace amounts of blood which also led me to believe that there were some 
kidney complications. According to Halvorson et al, the presence of three or more cysts 
either unilaterally or bilaterally is adequate to diagnose ADPKD in patients between 15-
30 years of age. Similarly patients aged 40-59 require the presence of at least two cysts 
on each kidney, and patients aged 60 or above require at least four cysts in each kidney 
(2010). As seen on the ultrasound report, Mr. Powers has three bilateral renal cysts on his 
left kidney. Furthermore, Max mentioned that he does vaguely remember that his father 
did have cysts in his kidneys. The presentation of Max’s kidneys and the test results make 
all the other diagnoses unlikely. Genetic testing could also be used to solidify the 
diagnosis and also determine whether Max has a PKD1 or PKD2 mutation.  
Treatment Plan 
 Unfortunately, there is no cure for ADPKD. The best treatment plan is to prolong 
renal function as long as possible and if Max develops end stage renal disease (Stage 5 
CKD), he will need to be placed on dialysis and eventually need a renal transplant.  
 The most important step that we can take with regards to prolonging renal 
function is to keep Max’s hypertension in check. According to the JNC 8, in patients with 
chronic kidney disease and older than 18 years of age, treatment with ACE inhibitors or 
Angiotensin II receptor blockers (ARB)  is needed if the patient has a blood pressure 
greater than 140/90 22. To do this, an ACE inhibitor such as Lisinopril was prescribed. 





can retard the progression of renal dysfunction in ADPKD patients (2010). Therefore, 
drugs like Valsartan can also be prescribed.  
Usually in ADPKD patients, statins are also prescribed to protect cardiac 
function, however in Max’s case, since his cholesterol is in check, statins do not seem 
necessary 23. However, if his cholesterol levels start to increase, a statin will be 
prescribed.  
In addition, treatment of ADPKD also involves the treatment of symptoms such 
as pain in the abdominal region. For dull and minor pain or discomfort, Tylenol is 
recommended. If pain becomes too unbearable for Max, a short course of narcotic 
analgesic should be prescribed. NSAIDS should be avoided due to their negative effects 
on the kidneys and its reducing effect on ACE inhibitors. In extremely severe cases, cyst 
decortication may also be considered 4.   
With regards to his mild headaches, hopefully treatment of his hypertension will 
resolve the issue. Also he was asked to improve his sleeping as it may also be a 
contributing factor. If he wants, Tylenol can be used to alleviate pain.  
Prognosis 
Max’s renal function will need to be regularly monitored. His kidney function 
will need to be tested regularly by following his BUN, creatinine and GFR levels. Many 
ADPKD patients die not from the defective kidneys, but rather from secondary 
complications with the most common being heart disease. Therefore cardiac function 





based off of his GFR (within GFR 30-59ml/min) 24. If he enters Stage 4 CKD (GFR 15-
30ml/min), it is recommended that he sees a nephrologist. If he starts to go into end stage 
renal disease (GFR <15ml/min), his name will be placed on the kidney transplant list. He 
will also be placed on dialysis. He will need a kidney transplant.  
Lifestyle steps Max should take are to consume a low salt and protein diet, and 
exercise regularly 4. He should also increase fluid intake. Furthermore he should 
constantly monitor his blood pressure and let us know if it does not decrease.  In addition, 
he may want to start talking to friends and family about his situation and the need for a 
possible kidney transplant.  
Furthermore, Max may want to consult a genetic counselor. Since ADPKD is an 
autosomal dominant disease, he has 50% chance of passing it on, should he decide to 
have kids. Furthermore, since his father is believed to have kidney cysts, there is a strong 
possibility that he had ADPKD and died from a heart attack that was induced by his 
failing kidneys. His sister might also want to be tested for ADPKD so she can start taking 
the necessary precautions if needed. She can obtain a genetic test in which the PKD 
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